{
    "eid": "2-s2.0-84989167977",
    "title": "Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children",
    "cover-date": "2016-10-17",
    "subject-areas": [
        {
            "$": "Public Health",
            "@code": "2739"
        },
        {
            "$": "Molecular Medicine",
            "@code": "1313"
        },
        {
            "$": "General Immunology and Microbiology",
            "@code": "2400"
        },
        {
            "$": "General Veterinary",
            "@code": "3400"
        },
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        }
    ],
    "keywords": [
        "Children",
        "Immunogenicity",
        "Japanese encephalitis vaccine",
        "Safety"
    ],
    "authors": [
        "Pakpoom Janewongwirot"
    ],
    "citedby-count": 8,
    "ref-count": 19,
    "ref-list": [
        "Japanese encephalitis surveillance and immunization - Asia and the Western Pacific, 2012",
        "Japanese encephalitis vaccines",
        "Estimated global incidence of Japanese encephalitis: A systematic review",
        "Protection against Japanese Encephalitis by Inactivated Vaccines",
        "Effectiveness of mouse brain-derived inactivated Japanese encephalitis vaccine in Thai National Immunization Program: A case-control study",
        "Adverse reactions to Japanese encephalitis vaccine",
        "Adverse events after Japanese encephalitis vaccination: Review of post-marketing surveillance data from Japan and the United States",
        "High stability of yellow fever 17D-204 vaccine: A 12-year restrospective analysis of large-scale production",
        "Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties",
        "Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax- JE) as a live, attenuated vaccine candidate against Japanese encephalitis",
        "Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: Randomized, controlled phase 3 immunogenicity and safety trial",
        "Safety and immunogenicity of a single administration of live-attenuated japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: Multicenter randomized controlled trial",
        "Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: A randomized study of immunogenicity and safety",
        "Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: Randomized, double-blind, 5-year phase II study in healthy adults",
        "Division of AIDS, National Institute of Allergy and Infectious Diseases",
        "Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children",
        "Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year after Primary Immunization in Healthy Children in the Republic of Korea",
        "Exp Rev Vaccines",
        "Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from South-East Asia and India"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Pathom",
            "affilname": "Mahidol University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Sanofi Pasteur",
        "Sanofi Pasteur",
        "Sanofi Pasteur",
        "Thailand Research Fund",
        "Thailand Research Fund",
        "Chulalongkorn University"
    ]
}